The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
Background and aim: Disproportionality analyses using reports of suspected adverse drug reactions are the most commonly used quantitative methods for detecting safety signals in pharmacovigilance. However, their methods and results are generally poorly reported in published articles and existing gui...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer
2024
|
| _version_ | 1817930893451329536 |
|---|---|
| author | Fusaroli, M Salvo, F Begaud, B AlShammari, TM Bate, A Battini, V Brueckner, A Candore, G Carnovale, C Crisafulli, S Cutroneo, PM Dolladille, C Drici, M Faillie, J Goldman, A Hauben, M Herdeiro, MT Mahaux, O Manlik, K Montastruc, F Noguchi, Y Norén, GN Noseda, R Onakpoya, IJ Sartori, D |
| author_facet | Fusaroli, M Salvo, F Begaud, B AlShammari, TM Bate, A Battini, V Brueckner, A Candore, G Carnovale, C Crisafulli, S Cutroneo, PM Dolladille, C Drici, M Faillie, J Goldman, A Hauben, M Herdeiro, MT Mahaux, O Manlik, K Montastruc, F Noguchi, Y Norén, GN Noseda, R Onakpoya, IJ Sartori, D |
| author_sort | Fusaroli, M |
| collection | OXFORD |
| description | Background and aim: Disproportionality analyses using reports of suspected adverse drug reactions are the most commonly used quantitative methods for detecting safety signals in pharmacovigilance. However, their methods and results are generally poorly reported in published articles and existing guidelines do not capture the specific features of disproportionality analyses. We here describe the development of a guideline (REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance [READUS-PV]) for reporting the results of disproportionality analyses in articles and abstracts. Methods: We established a group of 34 international experts from universities, the pharmaceutical industry, and regulatory agencies, with expertise in pharmacovigilance, disproportionality analyses, and assessment of safety signals. We followed a three-step process to develop the checklist: (1) an open-text survey to generate a first list of items; (2) an online Delphi method to select and rephrase the most important items; (3) a final online consensus meeting. Results: Among the panel members, 33 experts responded to round 1 and 30 to round 2 of the Delphi and 25 participated to the consensus meeting. Overall, 60 recommendations for the main body of the manuscript and 13 recommendations for the abstracts were retained by participants after the Delphi method. After merging of some items together and the online consensus meeting, the READUS-PV guidelines comprise a checklist of 32 recommendations, in 14 items, for the reporting of disproportionality analyses in the main body text and four items, comprising 12 recommendations, for abstracts. Conclusions: The READUS-PV guidelines will support authors, editors, peer-reviewers, and users of disproportionality analyses using individual case safety report databases. Adopting these guidelines will lead to more transparent, comprehensive, and accurate reporting and interpretation of disproportionality analyses, facilitating the integration with other sources of evidence. |
| first_indexed | 2024-09-25T04:16:28Z |
| format | Journal article |
| id | oxford-uuid:0f737c9e-ac6f-42d7-808d-099a77ddeedf |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:13:22Z |
| publishDate | 2024 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:0f737c9e-ac6f-42d7-808d-099a77ddeedf2024-10-16T09:15:57ZThe Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and StatementJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0f737c9e-ac6f-42d7-808d-099a77ddeedfEnglishJisc Publications RouterSpringer2024Fusaroli, MSalvo, FBegaud, BAlShammari, TMBate, ABattini, VBrueckner, ACandore, GCarnovale, CCrisafulli, SCutroneo, PMDolladille, CDrici, MFaillie, JGoldman, AHauben, MHerdeiro, MTMahaux, OManlik, KMontastruc, FNoguchi, YNorén, GNNoseda, ROnakpoya, IJSartori, DBackground and aim: Disproportionality analyses using reports of suspected adverse drug reactions are the most commonly used quantitative methods for detecting safety signals in pharmacovigilance. However, their methods and results are generally poorly reported in published articles and existing guidelines do not capture the specific features of disproportionality analyses. We here describe the development of a guideline (REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance [READUS-PV]) for reporting the results of disproportionality analyses in articles and abstracts. Methods: We established a group of 34 international experts from universities, the pharmaceutical industry, and regulatory agencies, with expertise in pharmacovigilance, disproportionality analyses, and assessment of safety signals. We followed a three-step process to develop the checklist: (1) an open-text survey to generate a first list of items; (2) an online Delphi method to select and rephrase the most important items; (3) a final online consensus meeting. Results: Among the panel members, 33 experts responded to round 1 and 30 to round 2 of the Delphi and 25 participated to the consensus meeting. Overall, 60 recommendations for the main body of the manuscript and 13 recommendations for the abstracts were retained by participants after the Delphi method. After merging of some items together and the online consensus meeting, the READUS-PV guidelines comprise a checklist of 32 recommendations, in 14 items, for the reporting of disproportionality analyses in the main body text and four items, comprising 12 recommendations, for abstracts. Conclusions: The READUS-PV guidelines will support authors, editors, peer-reviewers, and users of disproportionality analyses using individual case safety report databases. Adopting these guidelines will lead to more transparent, comprehensive, and accurate reporting and interpretation of disproportionality analyses, facilitating the integration with other sources of evidence. |
| spellingShingle | Fusaroli, M Salvo, F Begaud, B AlShammari, TM Bate, A Battini, V Brueckner, A Candore, G Carnovale, C Crisafulli, S Cutroneo, PM Dolladille, C Drici, M Faillie, J Goldman, A Hauben, M Herdeiro, MT Mahaux, O Manlik, K Montastruc, F Noguchi, Y Norén, GN Noseda, R Onakpoya, IJ Sartori, D The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement |
| title | The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement |
| title_full | The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement |
| title_fullStr | The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement |
| title_full_unstemmed | The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement |
| title_short | The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement |
| title_sort | reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance readus pv development and statement |
| work_keys_str_mv | AT fusarolim thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT salvof thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT begaudb thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT alshammaritm thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT batea thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT battiniv thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT bruecknera thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT candoreg thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT carnovalec thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT crisafullis thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT cutroneopm thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT dolladillec thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT dricim thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT failliej thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT goldmana thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT haubenm thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT herdeiromt thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT mahauxo thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT manlikk thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT montastrucf thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT noguchiy thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT norengn thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT nosedar thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT onakpoyaij thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT sartorid thereportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT fusarolim reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT salvof reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT begaudb reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT alshammaritm reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT batea reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT battiniv reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT bruecknera reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT candoreg reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT carnovalec reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT crisafullis reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT cutroneopm reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT dolladillec reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT dricim reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT failliej reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT goldmana reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT haubenm reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT herdeiromt reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT mahauxo reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT manlikk reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT montastrucf reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT noguchiy reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT norengn reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT nosedar reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT onakpoyaij reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement AT sartorid reportingofadisproportionalityanalysisfordrugsafetysignaldetectionusingindividualcasesafetyreportsinpharmacovigilancereaduspvdevelopmentandstatement |